Egfl8 Antibody

Introduction to Egfl8 Antibody

EGFL8 antibodies are immunoglobulins specifically designed to recognize and bind to the EGFL8 protein, also known as vascular endothelial statin-2 (VE-statin-2). These antibodies serve as critical tools for detecting, quantifying, and studying the functional roles of EGFL8 in various biological contexts. EGFL8 antibodies have been instrumental in elucidating the protein's involvement in thymic epithelial cell regulation, T-cell development, and potential roles in cancer progression .

The development and characterization of these antibodies have enabled researchers to investigate the expression patterns of EGFL8 across different tissues and cell types, as well as its functional implications in normal physiology and disease states. Most commercially available EGFL8 antibodies are polyclonal and produced in rabbits, with validated applications in multiple research techniques .

Structure and Characteristics of Egfl8 Antibodies

EGFL8 antibodies are primarily produced as polyclonal immunoglobulins, meaning they consist of a heterogeneous mixture of antibodies that recognize different epitopes on the EGFL8 protein. The most common host animal for EGFL8 antibody production is rabbit, although mouse-derived antibodies are also available .

These antibodies typically target specific regions of the EGFL8 protein, such as the C-terminal region or amino acids within positions 50-250 of the human EGFL8 sequence . The immunogens used for antibody production include synthetic peptides corresponding to human EGFL8 sequences, recombinant fragments, or fusion proteins .

Most commercial EGFL8 antibodies are supplied in buffer solutions containing preservatives such as sodium azide and stabilizers like glycerol. The formulations are designed to maintain antibody activity during storage and application .

Applications and Techniques Using Egfl8 Antibodies

EGFL8 antibodies have been validated for various laboratory techniques and applications. The primary applications include:

Western Blotting (WB)

EGFL8 antibodies are widely used in Western blotting to detect the presence and quantity of EGFL8 protein in tissue or cell lysates. The predicted molecular weight of human EGFL8 is approximately 32 kDa, corresponding to its 293 amino acid sequence. Multiple commercial antibodies have been validated for this application, demonstrating specific binding to EGFL8 in human cell lines such as Jurkat cells .

Immunohistochemistry (IHC)

Both conventional IHC and paraffin-embedded section IHC (IHC-P) techniques employ EGFL8 antibodies to visualize the distribution and localization of EGFL8 protein in tissue sections. These applications have been particularly valuable in examining EGFL8 expression in normal tissues and pathological samples, including cancer tissues. Working dilutions for IHC applications typically range from 1:50 to 1:200 .

Immunofluorescence (IF)

Some EGFL8 antibodies have been validated for immunofluorescence applications, allowing for high-resolution imaging of EGFL8 protein localization within cells and tissues. The Sigma-Aldrich HPA061173 antibody, for example, is recommended for immunofluorescence at concentrations of 0.25-2 μg/mL .

Enzyme-Linked Immunosorbent Assay (ELISA)

ELISA applications using EGFL8 antibodies enable quantitative detection of the protein in various biological samples. This technique has been validated for certain commercial antibodies, including the Proteintech 13836-1-AP .

Target Protein: EGFL8 Structure and Function

Understanding the structure and function of EGFL8 is essential for appreciating the significance of EGFL8 antibodies as research tools.

Gene and Protein Structure

The EGFL8 gene is located on chromosome 6 in humans and chromosome 17 in mice . It encodes a protein of 293 amino acids with a calculated molecular weight of approximately 32 kDa. The protein structure includes an amino-terminal signal peptide and two EGF-like domains, which are characteristic of the EGFL family .

The average G+C content of EGFL8 is 61.4%, indicating potential regulatory importance in gene expression. The protein contains significant structural homology with EGFL7, suggesting potential functional overlap or evolutionary relationships between these family members .

Expression Patterns

EGFL8 expression has been observed in various tissues and cell types, including endothelial cells. It has been identified as a secreted protein, suggesting that it may function through autocrine or paracrine mechanisms . EGFL8 has also been detected in gastric and colorectal cancer tissues, with expression levels correlating with tumor stage and prognosis .

Biological Functions

Research using EGFL8 antibodies has revealed several important biological functions of the protein:

1. Regulation of T-cell Development: EGFL8 plays a negative regulatory role in thymic epithelial cells (TECs) and thymocytes. It inhibits the expression of important molecules for T-cell development, including ICAM-1, IL-7, GM-CSF, and thymus-expressed chemokine (TECK) .

2. Cell Proliferation Inhibition: EGFL8 has been shown to inhibit the proliferation of cortical thymic epithelial cells (cTECs). This inhibitory effect appears to involve suppression of cell cycle progression and potential induction of apoptosis .

3. Modulation of Gene Expression: EGFL8 significantly influences the expression of genes related to various cellular processes, including:

   • Cell cycle regulation (CDK1, CDK4, CDK6, cyclin D1)

   • Apoptosis (Bcl-2, Bcl-xL)

   • T-cell development (FasL, Nrp1, IGFBP-4, Thbs1)

   • Chemokine signaling (CCL20, CXCL5, CXCL10, CXCL16)

   • Transcription factors (Irf7, NF-κB2)

   • Angiogenesis (Angptl1, VEGF-A, CD74)

4. Anti-angiogenic Activity: Evidence suggests that EGFL8 may have anti-angiogenic properties, potentially through modulation of angiogenic factors like Angptl1, VEGF-A, CD74, and NF-κB2 .

Research Findings Related to Egfl8 Antibodies

EGFL8 antibodies have facilitated significant research findings across multiple biological contexts:

EGFL8 in Thymic Function

Studies using EGFL8 antibodies have demonstrated that EGFL8 exerts inhibitory effects on thymic epithelial cells and thymocyte development. In gain- and loss-of-function experiments, researchers found that EGFL8 knockdown enhanced the expression of genes involved in thymopoiesis, whereas EGFL8 overexpression had suppressive effects .

Genome-wide expression profiling in EGFL8-overexpressing or -silenced mouse cortical TECs revealed 458 genes with a >2-fold change in expression levels. These differentially expressed genes were involved in numerous cellular processes, including cell cycle regulation, proliferation, migration, differentiation, and immune responses .

EGFL8 in Cell Proliferation

WST-1 analysis revealed that overexpression of EGFL8 inhibits cTEC proliferation. Mechanistically, EGFL8 knockdown was shown to elevate the expression of important cell cycle regulatory molecules, including CDK1, CDK4, CDK6, and cyclin D1, as well as anti-apoptotic genes like Bcl-2 and Bcl-xL .

EGFL8 in Angiogenesis

Research with EGFL8 antibodies has suggested potential anti-angiogenic roles for EGFL8. Differential gene expression analysis showed that VEGF-A expression was upregulated in EGFL8-silenced TECs and downregulated in EGFL8-overexpressing TECs, whereas Angpt1 expression showed the opposite pattern .

EGFL8 in Cancer

EGFL8 expression has been correlated with elevated tumor stage and poor prognosis in gastric and colorectal cancers, as demonstrated by immunohistochemical studies using EGFL8 antibodies . These findings suggest that EGFL8 may serve as a potential biomarker or therapeutic target in certain cancer types.

Technical Considerations for Egfl8 Antibody Usage

When using EGFL8 antibodies for research applications, several technical considerations should be taken into account:

Antibody Selection

The choice of EGFL8 antibody should be guided by the specific research application, target species, and epitope of interest. Different commercial antibodies target different regions of the EGFL8 protein and may exhibit varying specificities and sensitivities .

Working Dilutions and Concentrations

Optimal working dilutions vary depending on the application and specific antibody:

• For Western blotting: typically 1:1000 to 1:2000 dilution

• For immunohistochemistry: 1:50 to 1:200 dilution

• For immunofluorescence: 0.25-2 μg/mL

Future Perspectives and Applications

The development and utilization of EGFL8 antibodies continue to evolve, with several promising future directions:

Potential Biomarker Development

The correlation between EGFL8 expression and cancer progression suggests potential applications for EGFL8 antibodies in diagnostic and prognostic assays. Further validation in larger clinical cohorts could establish EGFL8 as a valuable biomarker in certain cancer types .

Therapeutic Target Investigation

As EGFL8 appears to modulate multiple biological processes, including angiogenesis and cell proliferation, it represents a potential therapeutic target. EGFL8 antibodies could serve as valuable tools for target validation and potentially as therapeutic agents themselves .

Fundamental Research Applications

The continued use of EGFL8 antibodies in fundamental research will likely expand our understanding of EGFL8's roles in development, immunity, and disease processes. The demonstrated involvement of EGFL8 in thymic function, angiogenesis, and cell proliferation suggests numerous avenues for future investigation .